A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
A phase 2 trial of Calderasib and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) is a phase 2 interventional study registered as NCT07209111 by Merck Sharp & Dohme LLC, with 150 participants planned, started 2025-12-04 and due to reach its primary completion in 2032-04-09. Interventions recorded: Calderasib and Cetuximab.
Similar pages
not linked directly; found by shared links- TrialKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Shares Calderasib, Cetuximab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Shares Calderasib, Cetuximab, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.